Forge Therapeutics and Evotec to present preclinical data on novel antibiotic program at 2017 ASM/ESCMID Conference
San Diego, California, August 29, 2017 – Forge Therapeutics, Inc., [...]
Forge Therapeutics forms scientific advisory board with world renowned antibiotic and drug development experts
San Diego, California, July 26, 2017 – Forge Therapeutics, Inc., [...]
Forge Therapeutics to present at 2017 Bio International Convention
SAN DIEGO, California, June 12, 2017 – Forge Therapeutics, Inc., [...]
Forge and Evotec Present First Efficacy Data for LpxC Inhibitor in UTI Model at ASM Microbe 2017
San Diego, California, June 3, 2017 – Forge Therapeutics, Inc., [...]
Forge Therapeutics to present new data on novel Gram-negative antibiotic program at ASM Microbe 2017
San Diego, California, May 24, 2017 – Forge Therapeutics, Inc., [...]
Forge Therapeutics attracts biotechnology leaders to join expanded board of directors
Board Composed of San Diego Biotech Veterans, Global Drug Development [...]
Forge Therapeutics raises $15m Series A financing to develop first novel Gram-negative antibiotic in decades
Series A Complements Recent CARB-X Non-Dilutive Funding Forge Is Resourced [...]
Forge Therapeutics Wins Powered by CARB-X Research Award of $8.8M to Accelerate Development of its LpxC Antibiotic to Kill the World’s Deadliest ‘Superbugs’
San Diego, Calif., March 30, 2017 – Forge Therapeutics, Inc., [...]
Forge Therapeutics to Present at Biocom Global Life Science Partnering Conference
Company to discuss novel antibiotic program targeting LpxC to kill [...]
Forge Therapeutics to Present at the 9th Annual Biotech Showcase
San Diego, Calif., January 4, 2017 – Forge Therapeutics, Inc. [...]